Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186


Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C.

Clin Cancer Res. 2008 Jul 1;14(13):4175-85. doi: 10.1158/1078-0432.CCR-07-4470.


Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.

Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.


Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12. Epub 2005 Jul 11.


TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers.

Freudlsperger C, Bian Y, Contag Wise S, Burnett J, Coupar J, Yang X, Chen Z, Van Waes C.

Oncogene. 2013 Mar 21;32(12):1549-59. doi: 10.1038/onc.2012.171. Epub 2012 May 28.


Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.

Macha MA, Matta A, Chauhan SS, Siu KW, Ralhan R.

Carcinogenesis. 2011 Mar;32(3):368-80. doi: 10.1093/carcin/bgq278. Epub 2010 Dec 22.


PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.

Clin Cancer Res. 2009 May 15;15(10):3354-65. doi: 10.1158/1078-0432.CCR-08-2365. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2009 Jul 15;15(14):4784-5.


Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.


Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.


Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.

Mol Cancer Res. 2011 Feb;9(2):183-94. doi: 10.1158/1541-7786.MCR-10-0368. Epub 2011 Jan 11.


A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.

Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C, Chen Z.

Int J Cancer. 2008 May 1;122(9):1987-98. doi: 10.1002/ijc.23324.


Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.

Clin Cancer Res. 2007 Oct 1;13(19):5942-51. Erratum in: Clin Cancer Res. 2007 Nov 1;13(21):6543.


Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.

Nottingham LK, Yan CH, Yang X, Si H, Coupar J, Bian Y, Cheng TF, Allen C, Arun P, Gius D, Dang L, Van Waes C, Chen Z.

Oncogene. 2014 Feb 27;33(9):1135-47. doi: 10.1038/onc.2013.49. Epub 2013 Mar 4.


CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.

Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF.

Oral Oncol. 2012 Jul;48(7):585-93. doi: 10.1016/j.oraloncology.2012.01.012. Epub 2012 Feb 17.


Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE.

Mol Cancer Ther. 2009 Aug;8(8):2211-20. doi: 10.1158/1535-7163.MCT-09-0327. Epub 2009 Jul 28.


ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation.

Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J, Duggal P, Allen C, Chuang R, Ehsanian R, Si H, Sinha S, Van Waes C, Chen Z.

Cancer Res. 2011 May 15;71(10):3688-700. doi: 10.1158/0008-5472.CAN-10-3445. Erratum in: Cancer Res. 2011 Dec 1;71(23):7323.


Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, Calvo KR, Van Waes C, Chen Z.

Clin Cancer Res. 2009 Apr 1;15(7):2361-72. doi: 10.1158/1078-0432.CCR-08-1011. Epub 2009 Mar 24.


Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer.

Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C.

Clin Cancer Res. 2009 Oct 1;15(19):5974-84. doi: 10.1158/1078-0432.CCR-09-1352. Epub 2009 Sep 29.

Items per page

Supplemental Content

Write to the Help Desk